<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274663</url>
  </required_header>
  <id_info>
    <org_study_id>B1731001</org_study_id>
    <nct_id>NCT01274663</nct_id>
  </id_info>
  <brief_title>A Study Of PF-05175157 In Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability and
      pharmacokinetics of single oral doses of PF-05175157 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of escalating single doses of PF-05175157 in healthy subjects</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single dose pharmacokinetics of PF-05175157</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory pharmacodynamic biomarkers</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>10 mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>xxx mg PF-05175157 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.</description>
    <arm_group_label>10 mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.</description>
    <arm_group_label>30 mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.</description>
    <arm_group_label>100 mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.</description>
    <arm_group_label>300 mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.</description>
    <arm_group_label>600 mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.</description>
    <arm_group_label>800 mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157 or Placebo</intervention_name>
    <description>One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.</description>
    <arm_group_label>xxx mg PF-05175157 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female (non child-bearing potential) subjects between the ages of
             18 and 45 years (inclusive).

          -  Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurements, 12-lead ECG and clinical laboratory tests.

          -  In addition, subjects must have normal chest x-ray, normal pulmonary function tests
             and normal ophthalmological examination.

          -  Body Mass Index (BMI) of 17.5 to 29.5 kg/m2; and a total body weight &gt; 50 kg (110
             lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
             disease (including drug allergies).

          -  Evidence or history of any chronic ongoing or current pulmonary disease.

          -  History of smoking in the past 5 years or history or evidence of habitual use of other
             (non-smoked) tobacco or nicotine-containing products within 3 months of Screening or
             positive cotinine test at Screening or Day 0.

          -  Active ocular disease including infection, glaucoma, seasonal allergies, dry-eye
             symptoms or retinal/optic nerve disease.

          -  Evidence or history of 'dry eye-syndrome', Meibomian gland disease, ocular
             inflammation (eg, uveitis, iritis), chronic blepharitis, any eye surgery including
             Lasik, any mechanical injury or chemical exposure to the ocular surface, use of ocular
             lubricants, or use of contact lenses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731001&amp;StudyName=A%20Study%20Of%20PF-05175157%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Safety and Tolerability</keyword>
  <keyword>PK</keyword>
  <keyword>Healthy Subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

